TNXP

Tonix Pharmaceuticals Holding Corp

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

The company also announced the pricing of a $20 million registered direct offering.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap raised their FY2025 earnings per share estimates for Tonix Pharmaceuticals in a report...

Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.

Tonix Pharmaceuticals on Monday announced the launch of its new drug to treat Fibromyalgia.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its quarterly earnings results on Monday. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus...

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.

The late-stage candidate TNX-102 SL has received FDA Fast Track status and has delivered positive results in two pivotal Phase 3 trials, demonstrating meaningful pain reduction.